A detailed history of Balyasny Asset Management LLC transactions in Apellis Pharmaceuticals, Inc. stock. As of the latest transaction made, Balyasny Asset Management LLC holds 50,000 shares of APLS stock, worth $1.5 Million. This represents 0.0% of its overall portfolio holdings.

Number of Shares
50,000
Previous 199,954 74.99%
Holding current value
$1.5 Million
Previous $7.67 Million 81.2%
% of portfolio
0.0%
Previous 0.01%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q2 2024

Aug 14, 2024

SELL
$38.07 - $59.71 $1.23 Million - $1.93 Million
-32,289 Reduced 13.9%
199,954 $7.67 Million
Q1 2024

May 13, 2024

BUY
$55.39 - $72.47 $12.9 Million - $16.8 Million
232,243 New
232,243 $13.7 Million
Q2 2023

Aug 14, 2023

SELL
$76.68 - $93.31 $24.1 Million - $29.3 Million
-313,728 Reduced 50.77%
304,169 $27.7 Million
Q1 2023

May 15, 2023

BUY
$46.59 - $66.96 $16.8 Million - $24.2 Million
361,556 Added 141.04%
617,897 $40.8 Million
Q4 2022

Feb 14, 2023

BUY
$43.24 - $61.04 $9.04 Million - $12.8 Million
209,076 Added 442.35%
256,341 $13.3 Million
Q3 2022

Nov 14, 2022

BUY
$44.76 - $69.66 $2.12 Million - $3.29 Million
47,265 New
47,265 $3.23 Million
Q1 2022

May 16, 2022

SELL
$35.46 - $54.12 $4.56 Million - $6.96 Million
-128,514 Closed
0 $0
Q4 2021

Feb 14, 2022

SELL
$30.74 - $49.16 $1.68 Million - $2.69 Million
-54,633 Reduced 29.83%
128,514 $6.08 Million
Q3 2021

Nov 15, 2021

BUY
$31.4 - $69.84 $5.75 Million - $12.8 Million
183,147 New
183,147 $6.04 Million
Q4 2018

Feb 14, 2019

SELL
$11.47 - $18.71 $688,200 - $1.12 Million
-60,000 Closed
0 $0
Q3 2018

Nov 14, 2018

SELL
$16.57 - $21.03 $89,941 - $114,150
-5,428 Reduced 8.3%
60,000 $1.07 Million
Q2 2018

Aug 14, 2018

BUY
$19.63 - $30.0 $1.28 Million - $1.96 Million
65,428 New
65,428 $1.44 Million

Others Institutions Holding APLS

About Apellis Pharmaceuticals, Inc.


  • Ticker APLS
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Biotechnology
  • Shares Outstandng 109,865,000
  • Market Cap $3.29B
  • Description
  • Apellis Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the discovery, development, and commercialization of therapeutic compounds through the inhibition of the complement system for autoimmune and inflammatory diseases. The company's lead product candidate is pegcetacoplan that is in Phase III clinical trials for...
More about APLS
Track This Portfolio

Track Balyasny Asset Management LLC Portfolio

Follow Balyasny Asset Management LLC and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Balyasny Asset Management LLC, based on Form 13F filings with the SEC.

News

Stay updated on Balyasny Asset Management LLC with notifications on news.